Literature DB >> 23867023

Utility of the U.S. Preventive Services Task Force criteria for diabetes screening.

Sarah Stark Casagrande1, Catherine C Cowie, Judith E Fradkin.   

Abstract

BACKGROUND: Federal law requires certain private insurers to cover and waive patient cost sharing for preventive medical services that receive a grade of B or better from the U.S. Preventive Services Task Force (USPSTF). The USPSTF recommends that asymptomatic adults who have a blood pressure (BP) higher than 135/80 mmHg be screened for type 2 diabetes.
PURPOSE: The goals of this study were to determine the sensitivity and specificity of the USPSTF screening criteria and to determine the prevalence of cardiovascular risk factors and comorbidity among undiagnosed individuals by USPSTF criteria.
METHODS: Data come from 7189 adults who participated in the 2003-2010 National Health and Nutrition Examination Survey; statistical analysis was conducted in 2011-2012. Participants with fasting plasma glucose ≥126 mg/dL or hemoglobin A1c (HbA1c) ≥6.5% who did not self-report a diagnosis of diabetes were categorized as having undiagnosed diabetes.
RESULTS: Among people without diagnosed diabetes, 4.0% had undiagnosed diabetes. The proportion of adults with undiagnosed diabetes who were identified (sensitivity) using BP >135/80 mmHg as the screening standard was 44.4%; among individuals without undiagnosed diabetes, 74.8% had BP ≤135/80 mmHg (specificity). For those with undiagnosed diabetes, the prevalence of HbA1c 7.0%-<8.0% was 10.6% for those with BP ≤135/80 mmHg and 14.3% for those with BP >135/80 mmHg; and 12.8% and 9.4% for HbA1c ≥8.0%, respectively. Elevated low-density lipoprotein (100-160 mg/dL) was similar by BP cut-point (52%-53%). For those with BP ≤135/80 mmHg, 16.7% had a history of cardiovascular disease and 22.9% had chronic kidney disease.
CONCLUSIONS: The USPSTF screening recommendations result in missing more than half of those who have undiagnosed diabetes, and a substantial proportion of these people have increased low-density lipoprotein and other cardiovascular risk factors.
Copyright © 2013 American Journal of Preventive Medicine. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23867023      PMCID: PMC3752602          DOI: 10.1016/j.amepre.2013.02.026

Source DB:  PubMed          Journal:  Am J Prev Med        ISSN: 0749-3797            Impact factor:   5.043


  20 in total

Review 1.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

2.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

Authors:  David M Nathan; Patricia A Cleary; Jye-Yu C Backlund; Saul M Genuth; John M Lachin; Trevor J Orchard; Philip Raskin; Bernard Zinman
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

3.  American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan.

Authors:  Yehuda Handelsman; Jeffrey I Mechanick; Lawrence Blonde; George Grunberger; Zachary T Bloomgarden; George A Bray; Samuel Dagogo-Jack; Jaime A Davidson; Daniel Einhorn; Om Ganda; Alan J Garber; Irl B Hirsch; Edward S Horton; Faramarz Ismail-Beigi; Paul S Jellinger; Kenneth L Jones; Lois Jovanovič; Harold Lebovitz; Philip Levy; Etie S Moghissi; Eric A Orzeck; Aaron I Vinik; Kathleen L Wyne
Journal:  Endocr Pract       Date:  2011 Mar-Apr       Impact factor: 3.443

4.  Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Authors:  William C Knowler; Elizabeth Barrett-Connor; Sarah E Fowler; Richard F Hamman; John M Lachin; Elizabeth A Walker; David M Nathan
Journal:  N Engl J Med       Date:  2002-02-07       Impact factor: 91.245

5.  A new and simple questionnaire to identify people at increased risk for undiagnosed diabetes.

Authors:  W H Herman; P J Smith; T J Thompson; M M Engelgau; R E Aubert
Journal:  Diabetes Care       Date:  1995-03       Impact factor: 19.112

6.  Diabetes Risk Calculator: a simple tool for detecting undiagnosed diabetes and pre-diabetes.

Authors:  Kenneth E Heikes; David M Eddy; Bhakti Arondekar; Leonard Schlessinger
Journal:  Diabetes Care       Date:  2007-12-10       Impact factor: 19.112

7.  Screening for type 2 diabetes mellitus in adults: recommendations and rationale.

Authors: 
Journal:  Ann Intern Med       Date:  2003-02-04       Impact factor: 25.391

8.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

9.  Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

Authors:  K Pyŏrälä; T R Pedersen; J Kjekshus; O Faergeman; A G Olsson; G Thorgeirsson
Journal:  Diabetes Care       Date:  1997-04       Impact factor: 19.112

10.  The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent-to-treat analysis of the DPP/DPPOS.

Authors: 
Journal:  Diabetes Care       Date:  2012-04       Impact factor: 19.112

View more
  14 in total

1.  Performance of the 2015 US Preventive Services Task Force Screening Criteria for Prediabetes and Undiagnosed Diabetes.

Authors:  Matthew J O'Brien; Kai McKeever Bullard; Yan Zhang; Edward W Gregg; Mercedes R Carnethon; Namratha R Kandula; Ronald T Ackermann
Journal:  J Gen Intern Med       Date:  2018-04-12       Impact factor: 5.128

2.  Multilevel Variation in Diabetes Screening Within an Integrated Health System.

Authors:  Udoka Obinwa; Adriana Pérez; Ildiko Lingvay; Luigi Meneghini; Ethan A Halm; Michael E Bowen
Journal:  Diabetes Care       Date:  2020-03-05       Impact factor: 19.112

3.  Performance of a Random Glucose Case-Finding Strategy to Detect Undiagnosed Diabetes.

Authors:  Michael E Bowen; Lei Xuan; Ildiko Lingvay; Ethan A Halm
Journal:  Am J Prev Med       Date:  2017-03-06       Impact factor: 5.043

4.  Reconsidering the age thresholds for type II diabetes screening in the U.S.

Authors:  Sukyung Chung; Kristen M J Azar; Marshall Baek; Diane S Lauderdale; Latha P Palaniappan
Journal:  Am J Prev Med       Date:  2014-08-15       Impact factor: 5.043

5.  More than A1C: Types of success among adults with type-2 diabetes participating in a technology-enabled nurse coaching intervention.

Authors:  Sarina Fazio; Jennifer Edwards; Sheridan Miyamoto; Stuart Henderson; Madan Dharmar; Heather M Young
Journal:  Patient Educ Couns       Date:  2018-08-23

Review 6.  Screening for Diabetes and Prediabetes.

Authors:  Daisy Duan; Andre P Kengne; Justin B Echouffo-Tcheugui
Journal:  Endocrinol Metab Clin North Am       Date:  2021-07-12       Impact factor: 4.748

7.  Self-reported prevalence of diabetes screening in the U.S., 2005-2010.

Authors:  Sarah Stark Casagrande; Catherine C Cowie; Saul M Genuth
Journal:  Am J Prev Med       Date:  2014-09-16       Impact factor: 5.043

8.  Receipt of Glucose Testing and Performance of Two US Diabetes Screening Guidelines, 2007-2012.

Authors:  Kai McKeever Bullard; Mohammed K Ali; Giuseppina Imperatore; Linda S Geiss; Sharon H Saydah; Jeanine B Albu; Catherine C Cowie; Nancy Sohler; Ann Albright; Edward W Gregg
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

9.  Detecting type 2 diabetes and prediabetes among asymptomatic adults in the United States: modeling American Diabetes Association versus US Preventive Services Task Force diabetes screening guidelines.

Authors:  Timothy M Dall; K M Venkat Narayan; Karin B Gillespie; Paul D Gallo; Tericke D Blanchard; Mihaela Solcan; Michael O'Grady; William W Quick
Journal:  Popul Health Metr       Date:  2014-05-07

10.  Blood glucose screening rates among Minnesota adults with hypertension, Behavioral Risk Factor Surveillance System, 2011.

Authors:  Renée S M Kidney; James M Peacock; Steven A Smith
Journal:  Prev Chronic Dis       Date:  2014-11-26       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.